Inês Martins, PhD, managing science editor —

Inês holds a PhD in biomedical sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied cell and molecular biology and worked as a research fellow at multiple institutes. In addition to several college awards, Inês won the Pfizer Basic Research Award in 2012 for a research paper. She also has a graduate degree in data science.

Articles by Inês Martins

FDA Approves Darzalex Combo Therapy for Previously Treated Multiple Myeloma Patients

The U.S. Federal Drug Administration has approved a combination of the immunotherapies Darzalex (daratumumab), Pomalyst (pomalidomide) and dexamethasone as a multiple myeloma treatment, according to Darzalex’s developer, Janssen Biotech. The combo offers a new option for patients who fail to respond to two lines of therapy that include Revlimib (lenalidomide) and…

Caris Collaboration to Identify Eligible Participants for NCI-MATCH Trial

Caris Life Sciences is collaborating with the National Cancer Institute (NCI) to identify patients eligible to participate in the Phase 2 NCI-MATCH (Molecular Analysis for Therapy Choice) study, the largest precision medicine trial to date. Caris will also evaluate next-generation sequencing results for certain trial participants. The NCI-MATCH trial (NCT02465060) was designed to evaluate…

Trial to Assess NY-ESO SPEAR T-cells as Part of a Combo Therapy Against Multiple Myeloma

Patients with certain kinds of relapsed or refractory multiple myelomas can enroll in a clinical trial assessing a combination of NY-ESO SPEAR T-cells and Keytruda (pembrolizumab), according to the T-cell treatment’s developer, Adaptimmune Therapeutics. To qualify for the study, patients’ tumor cells must express the NY-ESO or LAGE-1 proteins, or both. Expression is…

Non-profit Cancer Therapy Consultant Patient Power Praises District of Columbia Law Limiting Co-pays

The non-profit cancer-therapy consulting group Patient Power is hailing a District of Columbia law that established patient co-pay ceilings on specialty medications for diseases like multiple myeloma. Co-pays are a common feature of American health insurance plans. The term refers to a patient paying part of the cost of prescriptions or healthcare…